PFO
PCRX icon

Pathstone Family Office’s Pacira BioSciences PCRX Stock Holding History

Pathstone Family Office’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-14
Closed -$1K – 214
2014
Q3 		$1K Buy
+14
New +$1.36K ﹤0.01% 307

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pathstone Family Office's PCRX Position: Q4 2014 in Review

Pathstone Family Office sold out of Pacira BioSciences (PCRX) in Q4 2014, closing a stake of 14 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in PCRX in Q3 2014 and held it in 1 quarter. The position peaked at $1K in Q3 2014. 200 funds tracked by Wall St. Rank hold PCRX as of Q4 2014.

  • Pathstone Family Office reported no remaining Pacira BioSciences position as of Q4 2014 after selling out during the quarter.
  • Pathstone Family Office sold 14 Pacira BioSciences shares in Q4 2014, an estimated $1K.
  • Pathstone Family Office first reported a position in Pacira BioSciences in Q3 2014 and held it in 1 quarter.
  • Pathstone Family Office's Pacira BioSciences position peaked at $1K in Q3 2014.
  • 200 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2014.

Based on Pathstone Family Office's 13F filing for Q4 2014, filed 6 Feb 2015.